Andrew Hirsch is the President and CEO of C4 Therapeutics, having joined in September 2020. With over 20 years in biotech, he previously held senior roles at Agios, BIND Therapeutics, Avila Therapeutics, and Biogen. He also serves on the board of Editas Medicine. Andrew holds an MBA from Dartmouth’s Tuck School and a BA in Economics from the University of Pennsylvania.